Repligen Corporation

Financials

Flusso di cassa derivante dalle attività operative 62.63 M119.02 M172.08 M113.92 M175.39 M117.42 M 117.42 M Flussi di cassa derivanti dalle attività di investimento -201.38 M-221.17 M-233.24 M-123.28 M-86.38 M-298.47 M -298.47 M Liquidità derivante dalle attività di finanziamento 305.92 M961 K-13.34 M248.96 M-82.9 M-15.21 M -15.21 M Liquidità libera 36.28 M47.74 M38.74 M74.93 M142.49 M91.69 M 91.69 M

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide.

RGEN

Financials

Repligen Corporation

Notizie

Repligen: Advancing, Yet Much More Work Ahead (NASDAQ:RGEN)

Repligen (RGEN) Down 13.5% Since Last Earnings Report: Can It Rebound?

H.C. Wainwright alza il target su Repligen per la forte crescita

Evercore prevede crescita della spesa biopharma sulla base dei dati del sondaggio

Repligen Corporation (RGEN) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Il Fair Value di InvestingPro ha segnalato in anticipo il calo del 30% di Repligen

Repligen alla Conferenza Leerink: crescita strategica e sfide

Repligen at Leerink Conference: Strategic Growth and Challenges

Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript

KeyBanc conferma il rating su Repligen grazie allo slancio dei prodotti

KeyBanc reiterates Repligen stock rating on product momentum

Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y